Respiratory tract infections
Early, accurate pathogen identification—from laboratories to emergency care and point-of-care settings—is crucial to informing effective respiratory tract infection control.
Infectious diseases are becoming increasingly difficult to manage. Everything we do must meet the current and future needs of patients. While much healthcare effort is devoted to preventing the spread of disease and associated treatments, less attention is paid to the impact these infections have on the broader healthcare landscape, particularly on laboratories.
Since 1968, Roche has been committed to delivering innovative diagnostics solutions, with a proud history at the forefront of infectious diseases. From the first real-time PCR instrument to the first compact real-time PCR system for on-demand infectious disease testing at the point of care, we redefined what is possible with automation and infectious disease solutions.
It is critically important that laboratories are equipped to handle sudden surges in demand in worst-case scenarios. With a strong commitment to innovating solutions for infectious diseases, we are always striving to meet our customers’ needs and improve patient care. Everything we do is rooted in science, collaborating with academic institutions, governments, and policymakers around the world to ensure all our solutions are robust, efficient and effective.
With a broad menu of high-quality IVD and open channel assay on flexible molecular systems and serology solutions, Roche is committed to partnering for building strong and resilient healthcare ecosystems.
Our global supply chain and efficient logistics help us consistently deliver, maintain, and supply our customers worldwide. We have built a robust network of over 60,000 suppliers, spanning 6 continents and over 80 countries, to secure a sustainable supply of solutions, reagents and consumables for our partners worldwide, even in times of crisis.1
Expert service and support can help position laboratories for success in addressing current and future infectious diseases management, while enabling scalability to react in an emergency situation.
Respiratory tract infections
Early, accurate pathogen identification—from laboratories to emergency care and point-of-care settings—is crucial to informing effective respiratory tract infection control.
Sexual health
Infections that impact our sexual health are estimated to affect more than 376 million people annually.2 Most infected individuals have few or no symptoms, making diagnostic testing critical to detect STIs and inform appropriate patient management.
Viral hepatitis
More than 300 million people are infected with the hepatitis B virus (HBV) or the hepatitis C virus (HCV) and 9 out of 10 people living with viral hepatitis are unaware.3 Access to high-quality testing and treatment monitoring are important for managing the burden of this disease.4
Congenital infections
During pregnancy, several pathogens can be vertically transmitted to a foetus or newborn.5 The newborn period is often the only point at which laboratory testing and follow-up allow confirmation of a congenital infection.6
Transfusion-transmitted infections
Blood and plasma donations are a selfless and life-saving gift, coming from over 118.5 million donations globally each year.7 Diagnostics is critical in maintaining transfusion blood supply.
Transplant transmitted infections
An estimated 139,024 solid organ transplants are performed every year worldwide.8 Reliable diagnostic testing performed pre-or post-transplantation plays a key role in transplanting the gift of life.
Vector-borne disease
Vector-borne diseases are caused by parasites, viruses and bacteria that are transmitted by vectors. They account for more than 17% of all infectious diseases and cause over 700K deaths annually.9 Diagnostics are critical for informing appropriate patient and disease management.
Antimicrobial stewardship
Diagnostics play a critical role in antimicrobial stewardship efforts and support the timely identification of drug-resistant pathogens.
7-10% of patients in developing countries acquire healthcare associated infections (HAIs), and it is the most frequent adverse event in healthcare settings worldwide.10
To complicate these infections, approximately 700,000 people die each year globally of antimicrobial-resistant infections – these types of infections are predicted to be a leading cause of death by 2050.11
Gastrointestinal (GI) Infections
Gastrointestinal (GI) Infections cause a significant infectious disease burden worldwide. It is important to understand the cause and its prevalence.
Infectious Disease Area Lead
Christian is the Infectious Disease Area Lead for Roche Diagnostics Australia. His focus is on the clinical and medical value of diagnostics and supporting their optimal use for patient and public health benefits. Christian holds a Bachelor of Biomedical Science from the University of Technology, Sydney, and has over 25 years' experience in the diagnosis and monitoring of infectious diseases.
Severin Schwan
Chairman of the Board of Directors of Roche Holding AG
Across the infectious disease landscape, Roche is committed to meeting the needs of patients, developing best-in-class diagnostic solutions to help laboratories effectively support the needs of their customers and communities.
Roche’s portfolio of solutions spans the entire patient journey, enabling laboratories of all sizes and disciplines to provide reliable results across key clinical areas.
Innovations to help address global diseases
Clinically validated Roche assays had comprehensive studies conducted during development and with external clinical sites. Over the last three decades, Roche has been on the front lines of outbreaks. In 1998, Roche founded the Global Surveillance Program to monitor changes to the HIV genome, but now monitors the genetic sequences of many diseases, ranging from viral pathogens like influenza and hepatitis to bacterial pathogens like Mycobacterium tuberculosis (MTB) and methicillin-resistant Staphylococcus aureus (MRSA). The programme remains a vital tool to improve the reliability of our assays and to monitor new and emerging threats so that we’re ready to rapidly respond with innovative solutions as soon as possible.
Decades of experience in setting the standard for infectious disease testing makes Roche the partner of choice for clinical trials around the world. Some Roche assays have even been trusted to define treatment cut-offs for some of the world’s most burdensome diseases.12
Meet our global team of experts that are prepared to support labs in whatever they need—from recognising opportunities to integrate data, resources, and people, to delivering the best possible care at every touch point.
As the impact of infectious disease grows, so does Roche’s commitment to solving these unmet needs.
Backed by a proven history of innovation and a vast pipeline of solutions, Roche is enabling laboratories across the globe to better manage this growing challenge with purpose-built products and programs.
References